Comparing these 28 targets with the 32 targets indicated for T2D in TTD, we found products of three genes (HSD11B1, PPARA, NR3C1) are targeted by drugs currently in clinical trials for T2D. This evidence concerns the gene PPARA and type 2 diabetes mellitus.